Novo Nordisk A/S (NYSE: NVO) has emerged as one of the most searched-for stocks on Zacks.com, drawing significant attention from investors tracking the pharmaceutical sector.
Shares of the Danish drugmaker have returned -0.8% over the past month, underperforming the Zacks S&P 500 composite, which posted a gain of +2.1% over the same period.
The Zacks Large Cap Pharmaceuticals industry, the category in which Novo Nordisk is grouped, has gained 6.2% over that same stretch, widening the gap further.
For the current quarter, Novo Nordisk is expected to post earnings of $0.83 per share, reflecting a year-over-year decline of -14.4% compared to the same quarter last year.
The Zacks Consensus Estimate for the current quarter has shifted -0.5% over the last 30 days, signaling modest but steady downward pressure on near-term earnings expectations.
Looking at the full fiscal year, the consensus earnings estimate of $3.45 indicates a year-over-year change of -12.9%, with the estimate itself edging down -0.4% over the past month.
For the following fiscal year, the consensus earnings estimate of $3.42 represents a further decline of -1.1% from what Novo Nordisk is projected to report in the current year.
On the revenue side, the consensus sales estimate for the current quarter stands at $11.35 billion, reflecting a year-over-year change of -2.9% from the prior-year period.
Full-year consensus revenue estimates of $45.63 billion and $45.71 billion for the current and next fiscal years represent changes of -2.4% and +0.2%, respectively, pointing to an expected stabilization in top-line performance.
Novo Nordisk’s most recently reported quarter told a notably different story, with revenues of $15.17 billion representing a dramatic year-over-year increase of +37.7%.
Earnings per share of $1.04 in that quarter compared favorably to $0.92 in the same period a year earlier, demonstrating the company’s capacity to grow its bottom line.
The reported revenues that quarter exceeded the Zacks Consensus Estimate of $11.13 billion by a substantial margin, translating into a revenue surprise of +36.27%.
The EPS surprise for that same quarter came in at +19.54%, and the company has now beaten consensus EPS estimates in each of the trailing four quarters.
Novo Nordisk has topped consensus revenue estimates two times over that same four-quarter trailing period, reflecting a mixed but broadly positive track record of outperformance.
On valuation, Novo Nordisk holds a Zacks Value Style Score of B, suggesting the stock is currently trading at a discount relative to its pharmaceutical peers.
Given the combined weight of earnings estimate revisions and related factors, Zacks assigns Novo Nordisk a Zacks Rank #3, categorized as a Hold, implying performance roughly in line with the broader market in the near term.
